Lymphocyte adoptive therapy represents a revolutionary approach to cancer treatment that harnesses the body’s own immune system to fight disease. This innovative method involves collecting, multiplying, and sometimes genetically modifying a patient’s immune cells before returning them to combat cancer—a process that has transformed the landscape of cancer care and offered new hope to patients who have exhausted other treatment options.

Turning the Body’s Defense into a Weapon Against Cancer

The goal of lymphocyte adoptive therapy is to strengthen the immune system’s natural ability to recognize and destroy cancer cells. This treatment approach focuses on enhancing the patient’s existing defenses rather than relying solely on external drugs or radiation. The therapy depends heavily on the type and stage of cancer, as well as individual patient characteristics such as overall health and previous treatment history.

Medical societies have established standard treatments for many cancers, but researchers continue to explore new therapeutic approaches through clinical trials. Lymphocyte adoptive therapy, also called adoptive cell therapy or cellular immunotherapy, represents one of the most promising areas of ongoing research. Unlike traditional treatments that work the same way for everyone, adoptive cell therapy can be personalized to target the specific features of each patient’s cancer.^[2]

The fundamental concept behind this treatment is straightforward: immune cells called T cells have the natural ability to recognize and attack cancer cells. However, cancer often finds ways to hide from or suppress these immune cells. Adoptive therapy overcomes these obstacles by collecting immune cells from the patient, growing them to large numbers in the laboratory, and then returning them in quantities powerful enough to overwhelm the cancer’s defenses.^[4]

Standard Approaches to Adoptive Cell Therapy

The most established form of lymphocyte adoptive therapy involves tumor-infiltrating lymphocytes, commonly known as TILs. These are T cells that have naturally migrated into a patient’s tumor, demonstrating that they already recognize the cancer cells as dangerous. The challenge is that there usually aren’t enough of these cells to eliminate the tumor completely, and the tumor environment actively works to shut them down.^[2]

TIL therapy begins with surgery to remove a piece of the patient’s tumor. Scientists then isolate the lymphocytes that have infiltrated the tumor tissue and identify which ones show the strongest reaction against the cancer cells. These selected cells are exposed to substances called growth factors—particularly a protein called interleukin-2 (IL-2)—that cause them to multiply rapidly in the laboratory. This expansion process typically takes between two and eight weeks, during which billions of cancer-fighting cells are produced.^[8]

Before the grown cells are returned to the patient, a preparatory treatment is administered. This usually involves chemotherapy and sometimes radiation therapy designed to reduce the number of other immune cells in the body. This step, called lymphodepletion, might seem counterintuitive—why reduce immune cells when trying to boost immunity? The reason is that removing existing immune cells creates space and resources for the newly infused TILs to thrive and function more effectively. It’s similar to clearing a garden of weeds before planting new seeds.^[8]

After the preparatory chemotherapy, the expanded TILs are infused back into the patient through a vein, much like a blood transfusion. Following the infusion, patients typically receive additional doses of interleukin-2 to help the transferred cells survive and multiply further inside the body. The entire process requires careful coordination between surgeons, laboratory specialists, and oncology teams.^[2]

The treatment has been most extensively studied in metastatic melanoma, a deadly form of skin cancer that has spread to other parts of the body. Research conducted at the National Cancer Institute showed that approximately 50% of patients with advanced melanoma who received TIL therapy experienced measurable tumor shrinkage, with some patients achieving complete disappearance of all detectable cancer. These responses could be long-lasting, providing years of disease control.^[5]

In February 2024, the United States Food and Drug Administration granted approval to lifileucel (marketed as Amtagvi), making it the first TIL therapy officially approved for treating cancer. Specifically, it was approved for adults with advanced melanoma who had previously tried other treatments such as immunotherapy or targeted therapies without success. This approval marked a significant milestone, as it was the first cellular therapy approved for any solid tumor.^[8][15]

Genetically Enhanced T Cell Therapies

While TIL therapy relies on naturally occurring immune cells, scientists have developed methods to genetically engineer T cells to give them enhanced cancer-fighting abilities. These approaches fall into two main categories: T cell receptor (TCR) therapy and chimeric antigen receptor (CAR) T cell therapy.^[4]

TCR therapy addresses a significant limitation of TIL therapy: not all patients have T cells that naturally recognize their tumors. In TCR therapy, scientists collect regular T cells from a patient’s blood and insert genes that code for a specific T cell receptor—essentially a targeting system that allows the cell to recognize cancer cells. This receptor is designed to recognize cancer-specific proteins called antigens that are presented on the cancer cell’s surface in combination with molecules called major histocompatibility complex (MHC). Once equipped with this new receptor, the T cells can be expanded in the laboratory and returned to the patient, where they seek out and destroy cancer cells displaying the targeted antigen.^[4]

CAR T cell therapy represents an even more sophisticated approach to genetic engineering. Instead of a natural T cell receptor, scientists create an entirely synthetic receptor called a chimeric antigen receptor. The term “chimeric” means it’s made from parts of different molecules combined together. This artificial receptor has a crucial advantage: it can recognize cancer antigens directly on the cell surface without requiring MHC molecules to present them. This means CAR T cells can attack cancer cells even when they try to hide by reducing their MHC molecules—a common cancer escape mechanism.^[8]

The process for CAR T cell therapy begins with collecting T cells from the patient’s blood through a procedure called leukapheresis, which separates white blood cells from other blood components. These T cells are then sent to specialized laboratories where they are genetically modified to produce the CAR. The modification process uses viral vectors—modified viruses that can safely deliver new genetic material into cells. After the cells are engineered, they are grown to large numbers and undergo quality testing before being frozen and shipped back to the treatment center.^[6]

Six CAR T cell therapies have received FDA approval, all for treating blood cancers such as leukemias, lymphomas, and multiple myeloma. These approved therapies include axicabtagene ciloleucel (Yescarta), brexucabtagene autoleucel (Tecartus), ciltacabtagene autoleucel (Carvykti), idecabtagene vicleucel (Abecma), lisocabtagene maraleucel (Breyanzi), and tisagenlecleucel (Kymriah). Most of these target a protein called CD19 found on the surface of certain blood cancer cells.^[8]

These CAR T cell therapies have produced remarkable results in blood cancers, with some patients achieving complete remission even after all other treatments had failed. The success in blood cancers has led many patients to experience years of cancer-free survival, representing a true breakthrough in cancer treatment.^[6]

Investigating New Applications in Clinical Trials

While adoptive cell therapy has achieved its greatest success in melanoma and blood cancers, researchers are actively testing these approaches in many other cancer types through clinical trials. Solid tumors—cancers that form masses in organs like the breast, lung, colon, or brain—present unique challenges that are being addressed through innovative research.^[6]

Clinical trials testing TIL therapy have shown promising results in several solid tumor types beyond melanoma. Studies have reported encouraging findings in cervical squamous cell carcinoma and cholangiocarcinoma (a rare bile duct cancer). However, these applications remain experimental, meaning they are still being tested in clinical trials and are not yet approved as standard treatments. Researchers are working to understand why TILs work well for some cancer types but not others, with the goal of expanding the range of cancers that can be treated.^[8]

Several obstacles have emerged when applying adoptive cell therapy to solid tumors. Unlike blood cancers where the cancer cells circulate freely, solid tumors create a physical barrier that makes it difficult for T cells to penetrate. Additionally, the environment inside solid tumors is often hostile to immune cells, containing signals that suppress their function and cells that actively work against them. Researchers refer to this as the immunosuppressive tumor microenvironment.^[6]

To overcome these barriers, scientists are developing several innovative strategies currently being tested in clinical trials. One approach involves combining adoptive cell therapy with checkpoint inhibitors—drugs that block proteins like PD-1 and CTLA-4 that normally put brakes on immune responses. By combining engineered T cells with checkpoint inhibitors, researchers hope to create a more powerful anti-cancer response than either therapy could achieve alone. Early-phase trials are evaluating these combinations in various solid tumor types.^[6]

Another strategy involves creating “next-generation” CAR T cells with additional capabilities. Some experimental CAR T cells are being engineered to produce substances that counteract the immunosuppressive tumor environment. For example, researchers are testing CAR T cells that secrete their own checkpoint inhibitor molecules or that produce substances to help them survive in the harsh tumor environment. These modifications are designed to help the T cells maintain their cancer-fighting abilities even when surrounded by suppressive signals.^[6]

Clinical trials are also exploring multispecific CAR T cells that can recognize more than one cancer antigen simultaneously. This approach addresses a problem called antigen escape, where some cancer cells avoid destruction by losing the target antigen. If a CAR T cell can recognize multiple different antigens, the cancer has a harder time escaping. These trials are in various phases, with some in early Phase I safety testing and others advancing to Phase II efficacy studies.^[6]

Researchers are investigating ways to improve the manufacturing process for adoptive cell therapies. Current methods require several weeks and sophisticated laboratory facilities, making the therapy expensive and limiting access. Clinical trials are testing more rapid expansion methods, automated manufacturing systems, and techniques to create “off-the-shelf” T cells from healthy donors rather than requiring cells from each individual patient. Such advances could make these therapies more widely available.^[6]

Clinical trial phases follow a structured progression. Phase I trials primarily assess safety, testing the therapy in a small number of patients to identify the appropriate dose and watch for serious side effects. Phase II trials expand to more patients and focus on determining whether the therapy shows efficacy—does it actually shrink tumors or extend survival? Phase III trials are large studies that compare the new therapy directly against standard treatment to determine if it’s better. Many adoptive cell therapy trials for solid tumors are currently in Phase I or Phase II.^[6]

Eligibility for clinical trials varies depending on the specific study but typically includes factors such as cancer type and stage, previous treatments received, overall health status, and whether the tumor expresses the target antigen. Some trials require that patients have accessible tumor tissue for TIL generation or sufficient numbers of T cells in their blood for CAR T cell production. Clinical trials are being conducted at major cancer centers in the United States, Europe, and other regions worldwide. Patients interested in participating can discuss options with their oncologist or search clinical trial databases.^[6]

Understanding Treatment Side Effects

Like all cancer treatments, lymphocyte adoptive therapy can cause side effects. Understanding these potential effects helps patients and families prepare and allows medical teams to monitor and manage them promptly. The side effects differ somewhat between the preparatory treatments, the cell infusion itself, and the subsequent immune response.^[8]

The chemotherapy given before cell infusion to deplete existing immune cells causes side effects typical of chemotherapy, including low blood counts that can lead to increased infection risk, fatigue, nausea, and temporary hair thinning. These effects are generally manageable and resolve as the body recovers after treatment.^[2]

High-dose interleukin-2, which is often given after TIL infusion, can cause significant side effects including flu-like symptoms such as fever, chills, and body aches. It can also cause fluid retention leading to swelling and weight gain, low blood pressure requiring intensive monitoring, and in some cases, confusion or other mental status changes. Because of these potential effects, patients receiving high-dose IL-2 typically need to be hospitalized in specialized units where they can be closely monitored. Not all adoptive cell therapy protocols use high-dose IL-2, and researchers are investigating whether lower doses or alternative support medications might be equally effective with fewer side effects.^[15]

A unique set of side effects can occur specifically with CAR T cell therapy. One of the most significant is cytokine release syndrome (CRS), which happens when the infused T cells become activated and release large amounts of inflammatory substances called cytokines. Mild CRS may cause fever and fatigue, but severe cases can lead to dangerously high fevers, very low blood pressure, difficulty breathing, and reduced oxygen levels in the blood. CRS typically occurs within the first few days to weeks after cell infusion. Fortunately, medications are available to treat CRS, including a drug called tocilizumab that blocks a key inflammatory signal.^[8]

Another potential serious side effect of CAR T cell therapy is neurological toxicity, sometimes called immune effector cell-associated neurotoxicity syndrome (ICANS). This can cause confusion, difficulty speaking, tremors, seizures, or changes in consciousness. These symptoms usually appear within days to weeks after infusion and can range from mild to severe. Most neurological side effects resolve with time and supportive care, though some patients require medications to control symptoms.^[13]

Long-term side effects can include prolonged low blood counts, particularly low levels of normal B cells (the immune cells that produce antibodies), which can increase infection risk. Some patients require regular infusions of immunoglobulin (antibody replacement therapy) to help protect against infections. The duration of treatment varies by individual and cancer type, with some patients requiring ongoing monitoring for months or years after the initial cell infusion.^[8]

Most Common Treatment Methods

• Tumor-Infiltrating Lymphocyte (TIL) Therapy
  • Harvests T cells that have naturally infiltrated the patient’s tumor tissue
  • Selected lymphocytes are expanded to billions of cells over 2-8 weeks using interleukin-2
  • Requires surgical tumor removal to obtain starting material
  • Lifileucel (Amtagvi) approved by FDA for advanced melanoma in February 2024
  • Shows approximately 50% response rate in metastatic melanoma patients
  • Being tested in cervical cancer and cholangiocarcinoma in clinical trials
• CAR T Cell Therapy
  • T cells collected from patient’s blood through leukapheresis
  • Cells genetically engineered to express chimeric antigen receptors targeting cancer antigens
  • Six CAR T products approved for blood cancers: axicabtagene ciloleucel (Yescarta), brexucabtagene autoleucel (Tecartus), ciltacabtagene autoleucel (Carvykti), idecabtagene vicleucel (Abecma), lisocabtagene maraleucel (Breyanzi), and tisagenlecleucel (Kymriah)
  • Most target CD19 protein on leukemia and lymphoma cells
  • Can recognize cancer antigens without requiring MHC presentation
  • Being tested for solid tumors including breast and brain cancers in clinical trials
• Engineered TCR Therapy
  • Regular T cells equipped with new T cell receptors through genetic engineering
  • Allows targeting of specific cancer antigens presented by MHC molecules
  • Enables personalized selection of optimal target for each patient’s tumor
  • Can use T cells from the patient or from donors with matching human leukocyte antigens
  • Currently being evaluated in clinical trials for various cancer types
• Lymphodepleting Chemotherapy
  • Given before cell infusion to reduce existing immune cells
  • Creates space and resources for transferred T cells to function effectively
  • Sometimes combined with radiation therapy
  • Standard preparatory treatment for most adoptive cell therapy protocols
• Interleukin-2 Support Therapy
  • T cell growth factor given after cell infusion to support survival and expansion
  • High-dose IL-2 used in some TIL therapy protocols
  • Can cause significant side effects requiring intensive monitoring
  • Lower-dose alternatives being investigated to reduce toxicity